Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States

Giovanni Zanotti, Matthias Hunger, Julia J Perkins, Ruslan Horblyuk and Monique Martin

Abstract

Background: With several new therapies becoming available, treatment of metastatic breast cancer (mBC) is evolving. The objective of this study is to describe patient characteristics, treatment patterns and real-world clinical outcomes in post-menopausal women with ER+, HER2- mBC and to obtain insight into patient outcomes and potential unmet needs with current therapies.

Methods: The current study is a physician survey followed by a retrospective chart review of patient medical records by physicians in the US between March and April 2015. One hundred three physicians were asked to complete an online survey aiming to understand their satisfaction and expectations with current available treatments and potential areas of unmet need for mBC patients. Medical records from 178 females were extracted for the chart review. Using these data from medical records, patient characteristics and treatment patterns were analyzed descriptively. Time to progression (TTP) on first line, and progression-free survival (PFS) on second and third line of therapy were analyzed using the Kaplan-Meier method.

Results: Sixty-seven percent (n = 119) of patients had metastatic disease at initial diagnosis of breast cancer. Mean age at chart data extraction was 65.8 (SD: 9.4) years. Aromatase inhibitors (AIs) were prescribed for 58% and around 13% of patients in first line and second line, respectively. Chemotherapy was prescribed to 14% in first line and 31% in second line. Median TTP on first line therapy was 12 months for patients receiving AIs as compared to 7.9 months for patients receiving chemotherapy. Across all treatment lines, bone pain and fatigue were reported as the main symptoms associated with disease progression which had an impact on patient quality of life. Physicians expressed that prolonging life was deemed the most important treatment goal, followed by preservation or improvement of quality of life.

Conclusion: In this study the majority of patients received endocrine therapy as first line treatment and current therapies still resulted in a short time to progression in first line. Results from the chart review and the physician survey highlight a quantitative unmet need for more effective treatments which delay disease progression and improve survival outcomes while maintaining quality of life.

Keywords: Post-menopausal metastatic breast cancer, Treatment patterns, Physician survey, ER+/HER2
Background
Breast cancer (BC) is the most common cause of cancer death in women worldwide and estimated to be responsible for almost 460,000 deaths in 2008 [1]. Estimates from the United States for 2015 show that breast cancer accounts for 29% of all new cancers diagnosed and 15% of all cancer deaths in women [2,3]. When diagnosed in early stages, treatment of BC is generally more effective resulting in a 5-year overall survival rate of 99% for stage I (localised stage) and 85% on average in regional stage, compared with only 25% for the metastatic stage IV [2]. However, early stage BC can recur and it is estimated that 20 to 30% of all patients diagnosed with early stage BC will eventually progress to metastatic disease over a lifetime [4]. Metastatic breast cancer is when breast cancer has spread beyond the breast and local lymph nodes under the arm to other areas of the body. The most common sites of metastases are the bones, lungs, liver and brain.

Approximately 6–10% of new breast cancer cases are diagnosed initially at stage IV or mBC [5] and it has been estimated that 155,000 Americans are currently living with mBC [6]. According to the 2008 American Society of Clinical Oncology (ASCO) symposium report, the median survival rate after diagnosis of mBC was three years and no statistically significant improvement has been established since then [7,8].

The majority of diagnosed breast cancers is Estrogen receptor-positive (ER+) and Human Epidermal Growth Factor Receptor 2 negative (HER2-). Endocrine therapy is the major treatment for ER+ and HER2- metastatic breast cancer [9]. In the last two decades, the third generation of aromatase inhibitors anastrozole, letrozole and exemestane have become the standard hormonal treatment for post-menopausal women in both advanced and early disease [9]. The efficacy of these compounds in terms of response rates in first line metastatic patients are up to 40% with all initial responders eventually developing resistance over time, meaning that there is an ongoing need in this population [10].

According to the National Comprehensive Cancer Network (NCCN) guideline, it is recommended to continue endocrine therapy after progression with a first endocrine agent, unless there is significant visceral burden or rapid progression of disease, where in this case chemotherapy is recommended [11]. Other endocrine therapies options include selective oestrogen receptor modulators like tamoxifen or selective oestrogen receptor degraders like fulvestrant.

However, real world treatment patterns and outcomes among patients with ER+, HER2- mBC are still not well characterized. A literature review by Boswell et al. [12] examined disease burden and treatment outcomes in second-line therapy of patients with ER+ advanced breast cancer. The authors concluded that there is insufficient evidence on effectiveness outcomes to quantify the unmet need in ER+ patients, and this gap warrants further research. Swallow et al. [13] conducted an analysis of MarketScan databases of patients with HR+, HER2- mBC between 2002 and 2012. They found that most patients initiating treatment with endocrine therapy (ET) received only one line of ET before discontinuation or transition to chemotherapy. Gaps in knowledge remain despite the availability of recent chart review studies in HR+, HER2- mBC [14–16]. A better understanding of patient characteristics, real world variations in treatment and their impact on clinical outcomes is needed to identify limitations of currently available therapies and patient needs.

The objective of this study is to describe patient characteristics, clinical outcomes observed in real-world as well as identification of aromatase inhibitors early non responder’s characteristics in post-menopausal women with ER+, HER2- mBC and to obtain insight on potential unmet needs in these patients.

Methods
Data source
Our study had two distinct components: a cross-sectional physician survey and a retrospective medical record review conducted by participating physicians between March and April 2015. Physicians specializing in medical oncology or hematology/oncology and treating patients with post-menopausal ER+, HER2- metastatic breast cancer were invited to participate from a US online physician panel. Physicians were eligible for the survey and the chart review if they personally treated 12 or more ER+, HER2- metastatic breast cancer patients within the last six months. Also, physicians were required to provide informed consent and to have been practicing medicine for the treatment of ER+, HER2-mBC patients for between two and thirty years. To achieve a sample representative of physicians treating mBC in the US, soft quota restrictions were applied for the region where physicians practice and approximately 60% of sites were required to be community-based practices.

All potential physician participants were screened for study eligibility using a standardized screening questionnaire developed for the study. No more than two physicians were allowed to be grouped per practice. Eligible physicians were asked to participate in an online survey including 25 questions on physicians’ perception of quality of life among patients ER+, HER2- mBC, physicians’ satisfaction with currently available treatments and potential areas of unmet need, and physician and patient interactions and dialogue. The survey was pilot-tested on three physicians and minor changes
were made to the survey to reflect their comments. After completing the online survey, physicians were asked to extract individual patient data from medical records of two randomly selected patients and fill out an online case report form. Only de-identified data from the charts were abstracted and Institutional Review Board (IRB) approval was obtained for both the physician survey and the patient medical record data extraction components (Schulman IRB number 201500093). Research was performed in accordance with the Declaration of Helsinki.

**Patient selection**

Records of female patients were eligible for chart data abstraction if they had a confirmed post-menopausal status per local practice guidelines at time of mBC diagnosis, had a confirmed diagnosis of metastatic breast cancer based on histological or cytological findings and had confirmed ER+ and HER2- BC per local practice guidelines. Furthermore, patients had to have received care from the same physician from diagnosis of mBC to the last available encounter in the medical record and had to have completed at least 2 lines of breast cancer therapy in the mBC setting between January 1, 2008, and March 1, 2014. This means that patients that died during first-line therapy or before initiation of second-line therapy could not be enrolled in the study. Completion included completion of prescribed treatment, disease progression, or discontinuation of treatment due to adverse events, loss to follow-up, patient request, or death. Patients were not eligible for the chart review if they had evidence of other concurrent malignancy, except adequately treated non-melanoma skin cancer or other noninvasive (in situ) neoplasms at the time of diagnosis of ER+, HER2- metastatic breast cancer. Patients who participated in a clinical trial or other interventional study related to breast cancer for any treatment in the metastatic setting were not eligible for the study either. Participants of observational studies or adjuvant clinical trials were allowed. A quota for survival status was applied to the selection of patients to ensure that 80% of patients selected were still alive at the date of data abstraction.

**Study outcomes**

Chart data abstracted by the treating physician included information on demographic characteristics, disease history, treatments received by line of therapy, start and stop dates of the therapies, and reasons for treatment discontinuations. Primary reasons for discontinuation included – amongst others – completion of treatment as planned, disease progression, drug resistance, toxicities/side effects, or death. Time to disease progression on first-line therapy was defined as the time from the start of the therapy to the date of documented disease progression. Patients who completed first-line treatment as planned or who discontinued treatment for reasons other than disease progression were censored at the day of treatment completion or treatment discontinuation, respectively. As inclusion criteria required having completed at least two treatment lines, no deaths were observed during first line therapy. However, as some patients died while on second or third line therapy, progression-free survival (PFS) rather than TTP was analyzed for second and third line treatments. PFS on second and third line therapy was defined as the time from start of treatment to the date of documented disease progression or death. Patients who completed second or third line treatment as planned or who discontinued treatment for reasons other than disease progression were censored at the day of treatment completion or treatment discontinuation. Overall survival (OS) was defined as time from start of first-line treatment to death from any cause. For PFS and OS, patients without an event were censored at their chart abstraction date.

**Statistical analysis**

All statistical analyses were descriptive in nature. Summary statistics were calculated to describe physicians’ responses in the survey and to describe demographics, clinical characteristics, and treatment patterns of patients from the chart review study. For continuous data, the mean, standard deviation and median are presented. For categorical data (including yes/no categories), the frequency and percentage in each category are presented. Analyses were stratified by line of treatment and type of treatment received where applicable. Time-to-event endpoints such as TTP on first-line therapy, PFS on second or third line therapy or OS were analyzed using Kaplan-Meier methods to appropriately take into account censored observations.

To explore the potential unmet need of patients receiving aromatase inhibitors who had an early treatment discontinuation, further bivariate analyses in this subgroup were conducted. For these analyses, early treatment discontinuation was defined using a cut-off of five months. Reasons for treatment discontinuation included progression, death, drug resistance or toxicities/side effects.

**Results**

A total of 510 physicians were contacted through the online panel. Of those, 130 physicians were screened out because they did not meet inclusion criteria, and 277 physicians did not successfully complete the survey. A total of 103 physicians completed the survey and abstracted chart data from 178 post-menopausal patient medical records with confirmed ER+/HER2- mBC.
Chart review

Patient characteristics

Of the 178 patients with confirmed metastatic disease and for whom data was extracted 119 (66.9%) had metastatic disease at initial diagnosis of ER+ HER2- breast cancer (Table 1). Eleven percent were initially diagnosed at stage IIIA, IIIB or IIIC, while 40 (22.5%) patients had a history of early disease. The mean age at chart data extraction was 65.8 years. Distant metastases were most common in the bone (73.0%; n = 130) followed by lung/pleura (36.5%; n = 65), lymph nodes (32.0%; n = 57) and the liver (21.4%; n = 38). The mean age at progression to metastatic disease was 62.9 years. Most patients (89.3%, n = 159) had an Eastern Cooperative Oncology Group (ECOG) status of 0 or 1 at the time of diagnosis of mBC. For the 65 patients (36.5%) with a history of adjuvant treatment, median duration of adjuvant treatment was 36 months. Main reasons for stopping earlier, non-metastatic therapy were successful completion of planned treatment course (43.1%) and progression to metastatic disease (41.5%).

Treatment patterns

Aromatase inhibitors (anastrozole, letrozole and exemestane) were prescribed for the majority of patients in first line (103 out of 178; 58%) and for only 13% of patients in second line (23 out of 178). Other therapies (e.g. tamoxifen, fulvestrant or everolimus), or aromatase inhibitors combined with chemotherapy was given to 28% (50 out of 178) of patients in first line and 55.6% (99 out of 178) of patients in second line. Among the 50 patients receiving other therapies in first line, 43 patients were treated by endocrine therapy and the seven remaining patients were treated by everolimus (n = 4), bevacizumab (n = 2) and lapatinib (n = 1). Chemotherapy only was administered in 14.0% (25 out of 178) of patients in first line and in 31.5% (56 out of 178) of patients in second line (Fig. 1). Patients receiving chemotherapy in first line were more likely to have visceral disease than patients receiving other therapies (79.2% vs. 49.7%, p = 0.0071).

As shown in Fig. 2, the most frequently described treatment in first line was the aromatase inhibitor anastrozole (63 out of 178; 35.4% patients). Thirty-eight percent (n = 24) of patients receiving anastrozole in first line switched to fulvestrant in second line. Letrozole was administered in first line for 19.1% (34 out of 178) of patients. For these patients, the everolimus plus exemestane treatment combination and the fulvestrant endocrine therapy were the most frequently given subsequent treatment in second-line (for both everolimus + exemestane and fulvestrant: 32.4%; 11 out of 34). Exemestane was prescribed for only 3.4% of patients in first line (6 out of 178).

Table 1 Patients characteristics – from chart review

| Variable                                      | Level                   | N  | Mean | SD  |
|-----------------------------------------------|-------------------------|----|------|-----|
| Age at data extraction or death               |                         | 178| 65.83| 9.35|
| Age at initial BC diagnosis                   |                         | 178| 61.49| 9.69|
| Age at progression to metastatic disease      |                         | 178| 62.85| 9.39|
| Stage at diagnosis                            | Early (Stage IA, IB, IIA, IIB) | 40 | 22.5%|     |
|                                               | Limited Regional (Stage IIIA) | 8  | 4.5% |     |
|                                               | Locally Advanced (Stage IIIB) | 6  | 3.4% |     |
|                                               | Locally Advanced (Stage IIIC) | 5  | 2.8% |     |
|                                               | Metastatic (Stage IV)     | 119| 66.9%|     |
| ECOG performance status at the time of diagnosis of mBCa | 0                      | 63 | 35.4%|     |
|                                               | 1                       | 96 | 53.9%|     |
|                                               | 2                       | 18 | 10.1%|     |
|                                               | 3                       | 1  | 0.6% |     |
| Adjuvant treatment received (history)         | Yes                      | 65 | 36.5%|     |
|                                               | No                      | 111| 62.4%|     |
|                                               | Don’t know              | 2  | 1.1% |     |

BC breast cancer; ECOG: Eastern Cooperative Oncology Group; mBC: metastatic breast cancer

*aDefinition of ECOG performance statuses: 0: Fully active, able to carry on all pre-disease performance without restriction; 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g. light house work, office work; 2: Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3: Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
Aromatase Inhibitors
Other
Chemotherapy

**Fig. 1** Treatment patterns in first (panel a) and second line (panel b) – n = 178; from chart review. Aromatase inhibitors: anastrozole, letrozole, exemestane and anastrozole + exemestane. Chemotherapy: capecitabine, docetaxel, paclitaxel, paclitaxel + carboplatin, docetaxel + cyclophosphamide, 5 fluorouracil, carboplatin, carboplatin + gemcitabine, cyclophosphamide + doxorubicin, docetaxel + carboplatin, goserelin, nab- paclitaxel. Other: tamoxifen, fulvestrant, everolimus + exemestane, anastrozole + paclitaxel, anastrozole + fulvestrant, anastrozole + tamoxifen, anastrozole + docetaxel, bevacizumab, letrozole + fulvestrant, anastrozole + anthracycline + cyclophosphamide, anastrozole + paclitaxel + anthracycline, bevacizumab + anastrozole + tamoxifen, everolimus, everolimus + letrozole, everolimus + tamoxifen, exemestane + carboplatin, letrozole + zoledronic acid, letrozole + paclitaxel, tamoxifen + goserelin, vinorelbine + lapatinib, lapatinib, toremifene-citrate. Note: “Other” refers to other treatments than aromatase inhibitors and chemotherapy agents.

**Fig. 2** Treatment patterns after aromatase inhibitors in first line (n = 103) – from chart review. Data show absolute frequencies of treatments received in second line for patients that received anastrozole (n = 63), letrozole (n = 34) or exemestane (n = 6) in first line.
**Disease progression**

In first line, patients treated with chemotherapy progressed earlier (median time to disease progression: 7.9 months; 95% CI: 6.0 to 8.3) than those treated with aromatase inhibitors (12.0; 95% CI: 10.0 to 13.1) or other treatments including combination therapies of aromatase inhibitors and chemotherapy (11.9; 95% CI: 7.0 to 17.3), although the difference was not statistically significant – see Table 2. The Kaplan Meier curve for time to disease progression (TTP) in the subset of patients receiving aromatase inhibitors in first line (n = 103) shows that the probability of being progression-free at 3 and 5 months after start of first line therapy was 81.6% and 74.7% respectively (Fig. 3). In second line, median PFS was 7.3 (95% CI: 5.1 to 11.2), 7.4 (95% CI: 5.7 to 8.4) and 8.1 (95% CI: 7.0 to 12.0) months for patients receiving chemotherapy, aromatase inhibitors and other treatments, respectively. On third line treatment, the median PFS was higher for patients treated by chemotherapy compared with those treated by aromatases inhibitors and other treatments: 9.0 months for chemotherapy, 8.0 months (95% CI: 3.4 to 12.0) for aromatase inhibitors and 5.2 months (95% CI: 4.0 to 14.1) for other treatments.

As per inclusion criteria, 80% of patients were required to be alive at data abstraction. Accordingly, the Kaplan Meier estimate for the probability of survival at 24 months after start of first line treatment was 87.6%.

**Reasons for treatment discontinuations**

The most frequently reported primary reason of treatment discontinuation was efficacy in terms of disease progression and this was true for agents received in all the three first treatment lines. Disease progression accounted for 76.4% (168 out of 220 agents) of reasons reported in first line, 71.6% (169 out of 236 agents) of reasons in second line, and 50.4% (57 out of 113 agents) of reasons in third line (Table 3).

Across all treatment lines, bone pain and fatigue were reported as the most frequent symptoms associated with disease progression. Bone pain was reported for 54.4% (n = 81) of the 149 patients that progressed in first line and for 56.9% (n = 74) of the 130 patients that progressed in second line. Fatigue was reported for 41.6% (n = 62) of patients in first line and 43.8% (n = 57) of patients in second line.

**Characteristics of patients early discontinuing aromatase inhibitors**

Characteristics of patients who discontinued treatment with aromatase inhibitors earlier than 5 months after treatment initiation (n = 26) were not significantly different from the 76 patients who discontinued treatment later than 5 months (Table 4). However, early treatment discontinuation was less likely in patients receiving letrozole than in patients receiving anastrozole or exemestane (p = 0.0036).

**Physician survey**

**Physician characteristics**

Physicians had treated on average 30 pre- and 50 post-menopausal mBC ER+ HER2- patients in the past 6 months, respectively. Seventy-two of the 103 physicians were working in a clinic-based practice or had an office, whereas 13 physicians provided care in a community hospital based practice (25, 23, 25 and 30 physicians of the 103 physicians were based in North East, Middle-West, West and South, respectively). The remaining 18 physicians were from university hospitals, tumour centers or an NCI-designated cancer center.

According to the physicians surveyed, on average 32% of all their newly diagnosed post-menopausal BC patients had metastatic disease at initial diagnosis of BC.

---

**Table 2** Time to disease progression and PFS by drug category and treatment line – from chart review

| Variable | First-line treatment | n | # Censored obs. | Median (months) | 95% confidence interval | p-value<sup>b</sup> |
|----------|----------------------|---|----------------|----------------|------------------------|------------------|
|          |                      |   |                |                | Lower limit | Upper limit |      |          |
| Time to disease progression on first-line therapy | Aromatase inhibitors | 103 | 8 | 12.0 | 10.0 | 13.1 |          |
|          | Chemotherapy         | 25  | 13 | 7.9 | 6.0 | 8.3 |          |
|          | Other                | 50  | 8  | 11.9| 7.0 | 17.3| 0.3563  |
| Progression-free survival on second line therapy | Aromatase inhibitors | 103 | 16 | 7.4 | 5.7 | 8.4 |          |
|          | Chemotherapy         | 25  | 8  | 7.3 | 5.1 | 11.2|          |
|          | Other                | 50  | 19 | 8.1 | 7.0 | 12.0| 0.1047  |
| Progression-free survival on third-line therapy | Aromatase inhibitors | 55  | 23 | 8.0 | 3.4 | 12.0|          |
|          | Chemotherapy         | 11  | 6  | 9.0 | 1.4 | NE |          |
|          | Other                | 20  | 7  | 5.2 | 4.0 | 14.1| 0.9176  |

PFS Progression-free survival; NE Not Estimable

<sup>a</sup>Censored patients are patients who have not had an event of disease progression, either because they dropped out from the trial for reasons other than disease progression or because they had not progressed when data were cut-off. <sup>b</sup>log rank test
Thirty-three percent of patients were diagnosed at an early stage of BC (stage I or II) while the mean percentage of patients diagnosed at stage IIIA, IIIB or IIIC was 13%, 11% and 12% respectively.

**Treatment goals and treatment selection**

Physicians were asked about the three most important treatment goals for first-line therapy. As is shown in Table 5, prolonging life was deemed the most important reason for treatment (58.3%). The most frequently mentioned responses for the second most important reasons of treatment were quality of life improvement/preservation (23.3% for quality of life improvement and 19.4% for quality of life preservation), respectively. For the third most important reason, it was symptom relief (24.3%).

Physicians used hormonal therapies (aromatase inhibitors or tamoxifen) for around half of patients (51.9%) in first-line, followed by chemotherapy which was given to 17.6% of patients. In second-line, a fifth of patients received either oral hormonal therapy (21.1%), exemestane plus everolimus (22.4%) or other hormonal therapy (21.7%), respectively, and 25.6% of them were treated with chemotherapy. In third line, treatment patterns become even more diverse but with more patients receiving chemotherapy (35.8%): around 21.3% of patients received exemestane with everolimus and 12.6% and 16.3% of patients received oral hormonal and other hormonal therapy, respectively (Table 6).

**Expectations on and limitations of treatment success**

Physicians were asked to provide their experience with duration of PFS and OS for current treatments. In their

| Primary reason for treatment discontinuation | First line (*N* = 220) | Second line (*N* = 236) | Third line (*N* = 113) |
|---------------------------------------------|------------------------|-------------------------|------------------------|
| Disease progression                         | 168 (76.4%)            | 169 (71.6%)             | 57 (50.4%)             |
| Total completion of treatment               | 31 (14.1%)             | 30 (12.7%)              | 7 (6.2%)               |
| Toxicities or side effects                  | 14 (6.4%)              | 8 (3.4%)                | 7 (6.2%)               |
| Patient choice (non-financial)             | 4 (1.8%)               | 8 (3.4%)                | 5 (4.4%)               |
| Financial reasons                          | 1 (0.5%)               | 1 (0.4%)                | 1 (0.9%)               |
| Drug resistance                            | 2 (0.9%)               | 0 (0.0%)                | 1 (0.9%)               |
| Patient physical status                    | 0 (0.0%)               | 2 (0.8%)                | 1 (0.9%)               |
| Death related to mBC                       | 0 (0.0%)               | 5 (2.1%)                | 3 (2.7%)               |
| Death not related to mBC                   | 0 (0.0%)               | 2 (0.8%)                | 1 (0.9%)               |
| Treatment still ongoing                    | 0 (0.0%)               | 11 (4.7%)               | 30 (26.5%)             |

*There were more agents than patients per line (e.g. 220 agents vs. 178 patients in first line) as physicians were asked to provide reasons of discontinuation for every single agent rather than for every therapy*

*Number of agents*

---

Fig. 3 Time to progression on first line therapy with aromatase inhibitors – from chart review. Survivor function at 2 months: 0.845 / Survivor function at 3 months: 0.816 / Survivor function at 5 months: 0.747; median time to progression: 12.0 months

---

Zanotti et al. BMC Cancer (2017) 17:393
experience, duration of PFS for the first treatment in ER+ HER2- mBC patients is around 13 months. Physicians also reported that they consider on average an increase of 7.4 months (median 6 months) as the minimum clinically meaningful improvement in progression-free survival over current standard of care for a new treatment of post-menopausal ER+, HER2- mBC. In terms of overall survival from start of first treatment, physicians’ current experience was close to 29 months or 2.4 years.

The physicians were asked to list the main treatment limitations of current treatments on a scale from 1 to 5 (5: very substantial, 4: substantial, 3: moderately, 2: somewhat, 1: not at all substantial). The main limitations reported were efficacy and safety/tolerability of treatments (Table 7). Focusing on aromatase inhibitors only, efficacy was still the limitation that most physicians perceived as either substantial or very substantial (46.6%), but an equal proportion also considered drug resistance as a substantial or very substantial treatment limitation (Table 8).

### Table 4 Treatment discontinuation on first-line therapy with aromatase inhibitors before vs. after 5 months - from chart review

| Variable                        | Level                                      | Treatment discontinuation ≤ 5 months (N = 26) | Treatment discontinuation > 5 months (N = 76) | p-value  |
|---------------------------------|--------------------------------------------|---------------------------------------------|---------------------------------------------|----------|
| Stage at diagnosis              | Early (Stage IA, IB, IIA, IIIa)            | 5                                           | 12                                          | 0.4740   |
|                                 | Limited Regional (Stage IIIA)              | 2                                           | 1                                           | 1.3%     |
|                                 | Locally Advanced (Stage IIIb)              | 0                                           | 0                                           | 1.3%     |
|                                 | Locally Advanced (Stage IIIc)              | 0                                           | 2                                           | 2.6%     |
|                                 | Metastatic (Stage IV)                      | 19                                          | 60                                          | 78.9%    |
| ECOG performance status at the time of diagnosis of mBC a | 0                                           | 9                                           | 28                                          | 36.8%    | 0.8021   |
|                                 | 1                                           | 13                                          | 40                                          | 52.6%    |
|                                 | 2                                           | 4                                           | 8                                           | 10.5%    |
|                                 | 3                                           | 0                                           | 0                                           | 0.0%     |
| De novo / relapse               | De novo                                    | 19                                          | 61                                          | 80.3%    | 0.5575   |
|                                 | Relapse from adjuvant                       | 7                                           | 14                                          | 18.4%    |
|                                 | Don’t know                                  | 0                                           | 1                                           | 1.3%     |
| ECOG performance status at the time of diagnosis of mBC a | 0                                           | 9                                           | 28                                          | 36.8%    | 0.8021   |
|                                 | 1                                           | 13                                          | 40                                          | 52.6%    |
|                                 | 2                                           | 4                                           | 8                                           | 10.5%    |
|                                 | 3                                           | 0                                           | 0                                           | 0.0%     |
| De novo / relapse               | De novo                                    | 19                                          | 61                                          | 80.3%    | 0.5575   |
|                                 | Relapse from adjuvant                       | 7                                           | 14                                          | 18.4%    |
|                                 | Don’t know                                  | 0                                           | 1                                           | 1.3%     |
| Adjuvant treatment received     | Yes                                         | 8                                           | 17                                          | 22.4%    | 0.4328   |
|                                 | No                                          | 18                                          | 59                                          | 77.6%    |
|                                 | Don’t know                                  | 0                                           | 0                                           | 0.0%     |
| Aromatase inhibitors received in first-line | Anastrozole                                | 16                                          | 46                                          | 60.5%    | 0.0036   |
|                                 | Exemestane                                  | 5                                           | 1                                           | 1.3%     |
|                                 | Letrozole                                    | 5                                           | 29                                          | 38.2%    |
| Visceral disease                | Yes                                         | 15                                          | 31                                          | 40.8%    | 0.1349   |
|                                 | No                                          | 11                                          | 45                                          | 59.2%    |

mBC metastatic breast cancer

One patient using aromatase inhibitors in first-line was excluded due to treatment discontinuation (patient choice) at 3 months

*Definition of ECOG performance statuses; 0: Fully active, able to carry on all pre-disease performance without restriction; 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g. light house work, office work; 2: Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3: Capable of only limited self-care, confined to bed or chair more than 50% of waking hours

bExact Fisher test

experience, duration of PFS for the first treatment in ER+ HER2- mBC patients is around 13 months. Physicians also reported that they consider on average an increase of 7.4 months (median 6 months) as the minimum clinically meaningful improvement in progression-free survival over current standard of care for a new treatment of post-menopausal ER+, HER2- mBC. In terms of overall survival from start of first treatment, physicians’ current experience was close to 29 months or 2.4 years.

### Table 5 Goal of treatment – from physician survey (N = 103)

| Treatment Goal       | First Rank | Second Rank | Third Rank |
|----------------------|------------|-------------|------------|
| Prolongate life      | 60         | 58.3%       | 13         | 12.6%     | 14         | 13.6%     |
| Stabilize disease    | 1          | 1.0%        | 12         | 11.7%     | 11         | 10.7%     |
| Preserve Quality of life | 11       | 10.7%       | 20         | 19.4%     | 12         | 11.7%     |
| Delay chemotherapy   | 5          | 4.9%        | 6          | 5.8%      | 18         | 17.5%     |
| Symptom relief       | 5          | 4.9%        | 18         | 17.5%     | 25         | 24.3%     |
| Tumour shrinkage     | 9          | 8.7%        | 10         | 9.7%      | 7          | 6.8%      |
| Improve quality of life | 12       | 11.7%       | 24         | 23.3%     | 16         | 15.5%     |

The present study investigated patient characteristics, treatment patterns and time to disease progression through a retrospective review of medical records from ER+/HER2- mBC patients in the US and also assessed characteristics of patients experiencing early treatment discontinuation. Furthermore, the empirical real-world data from the chart review were supplemented, for some aspects, by a physician survey conducted among the 103 physicians who extracted the data.

### Discussion

The present study investigated patient characteristics, treatment patterns and time to disease progression through a retrospective review of medical records from ER+/HER2- mBC patients in the US and also assessed characteristics of patients experiencing early treatment discontinuation. Furthermore, the empirical real-world data from the chart review were supplemented, for some aspects, by a physician survey conducted among the 103 physicians who extracted the data.
The chart review data showed that following mBC diagnosis, the majority of patients received endocrine therapy (82%, including 58% (103/178) of aromatase inhibitors and 24% (43/178) of other ET) as a first-line treatment, with the aromatase inhibitors anastrozole and letrozole being the most frequently prescribed therapies. However, a significant proportion (14%) of patients received chemotherapy (including chemo monotherapy or chemo combination therapies) as the first-line treatment. The potential reasons for chemotherapy use in first line could be concerns about endocrine resistance or the higher frequency of visceral metastases among these patients [17].

These findings are consistent with previous studies examining treatment patterns in ER+/HER2- mBC patients: Macalalad et al. (2015) [15] who described treatment patterns in post-menopausal women with HR+/HER2- metastatic breast cancer in a US retrospective chart review, presented first line treatment patterns with 84% of patients treated with endocrine therapy (or treatment in combination with ET), 14% of them with chemotherapy (monotherapy or combination of chemotherapy agents) and 2% with other therapies (n = 144). Xie et al. performed a chart review in the US for the same population of patients, they showed that 87% and 13% of them were under endocrine therapy and chemotherapy respectively at baseline in patients with a single metastasis [16].

The median time to progression for patients included in this chart review who were treated with aromatase inhibitors in first line was 12 months. This is consistent with estimates from previous studies which reported a time to progression between 8.2 months and 13.1 months for anastrozole used in first line [18–20]. With a median of 8 months, time to progression during first-line therapy for patients receiving chemotherapy was markedly shorter. Median PFS on second line therapy was shorter than on first line and did not significantly differ by type of therapy received in first line. Regarding patients treated by aromatase inhibitors in first line, the median time to progression in third line was similar for those treated either by chemotherapy or aromatase inhibitors (9 months and 8 months respectively). This last clinical outcome is consistent with the NCCN guideline who recommends chemotherapy after three sequential endocrine therapy regimens. However chemotherapy is associated with important side effects which impair patient quality of life.

The overall findings of the study highlight a quantitative unmet need for more effective treatments which delay disease progression and improve survival outcomes while maintaining quality of life. This was also expressed by the physicians, who participated in the survey, stating that prolongation of life, delaying deterioration in symptoms, and preserving or improving quality of life represent the most important treatment goals for them. Also, the physicians expressed that they believed that, in the future, treatments should be more targeted to improve patient quality of life.

Table 6: Treatment selection: Proportion of therapies for post-menopausal ER+, HER2- metastatic BC patients used in first-line, second-line and third-line in the past 6 months – from physician survey (n = 103)

| Treatment                                  | First Line |   | Second Line |   | Third Line |   |
|---------------------------------------------|------------|---|-------------|---|------------|---|
| Oral hormonal therapy (e.g., tamoxifen, aromatase inhibitors) | 51.91% 32.48 | 21.14% 22.40 | 12.55% 15.02 |
| Other hormonal (e.g., fulvestrant)         | 11.68% 17.54 | 21.66% 23.76 | 16.32% 19.98 |
| Chemotherapy                               | 17.55% 18.43 | 25.58% 23.12 | 35.83% 27.27 |
| Exemestane plus Everolimus                 | 9.50% 14.44 | 22.38% 24.41 | 21.26% 23.71 |
| Avastin plus chemotherapy                  | 4.19% 9.73  | 4.91% 10.44 | 6.17% 14.42 |
| Clinical trial                             | 1.90% 6.16  | 2.34% 6.20  | 3.89% 9.27  |
| Other                                       | 3.25% -          | 2.00% -          | 3.97% -          |

BC Breast cancer; SD standard deviation

Table 7: Limitations of treatment success in first-line ER+, HER2- mBC patients – overall by analysis of categories – from physician survey (n = 103)

| Category                      | Not at all substantial | Not at all substantial | Moderately substantial | Substantial | Very substantial |
|-------------------------------|-----------------------|-----------------------|-----------------------|-------------|-----------------|
| n | %       | n | %       | n | %       | n | %       | n | %       | n | %       |
| Efficacy                      | 7 | 6.8%   | 12 | 11.7%  | 25 | 24.3%  | 25 | 24.3%  | 34 | 33.0%  |
| Safety/Tolerability           | 5 | 4.9%   | 22 | 21.4%  | 27 | 26.2%  | 35 | 34.0%  | 14 | 13.6%  |
| Adherence                     | 16 | 15.5%  | 29 | 28.2%  | 22 | 21.4%  | 27 | 26.2%  | 9  | 8.7%   |
| Financial cost of treatments  | 2 | 1.9%   | 27 | 26.2%  | 30 | 29.1%  | 35 | 34.0%  | 9  | 8.7%   |

mBC metastatic breast cancer
the majority of physicians considered limited efficacy as the most substantial limitation of currently available treatments. Finally, the survey also indicated that physicians consider an increase in progression-free survival of 7 months or more as more clinically relevant to patients.

The chart review observed that 74.5% of patients treated with aromatase inhibitors in first line have not experienced disease progression after 5 months, while 25.5% of patients did. It was hypothesised that this group of early progressors represents a subgroup of patients who are early non-responders to aromatase inhibitors and who ideally should be prescribed another treatment after progression or ideally should be identified early so that early progression can be prevented by using a different treatment. The current study was not able to identify specific clinical or patients characteristics that could be predictive of early non-responders, mainly due to the low numbers of patients available for this analysis. However, there were fewer patients treated with letrozole in first line who discontinued before 5 months as compared to those continuing beyond 5 months (5 (19.2%) vs. 29 (38.2%), \( p = 0.0036 \)). This might be related to potentially better efficacy of letrozole in comparison with other aromatase inhibitors. In previous in vivo measurement studies, letrozole demonstrated a better biochemical efficacy with a greater suppression of plasma oestrogen levels than anastrozole at clinical doses [21, 22]. However, a 5-year comparative efficacy study of letrozole and anastrozole in post-menopausal hormone receptor-positive early BC didn’t demonstrate any significant difference in disease free progression and survival rates [23].

Despite clear guidelines on the preferential use of multiple lines of endocrine therapy versus chemotherapy in advanced ER+ BC, a review of practice patterns using data from 2004 to 2010 have shown that these therapies were not being used as recommended [15]. The current study provides a more recent review of practice patterns in a rapidly evolving treatment landscape using data from 2008 to 2014. The study further adds to current knowledge on real-world outcomes in mBC since previous studies did not report data on clinical outcomes such as time to progression [13, 15]. Also, similar chart review studies in mBC patients did not describe treatment patterns [14, 16] or evaluated the effectiveness of specific treatment options only [14, 24]. Finally, by providing both, quantitative data from a chart review and qualitative data from the accompanying physician survey, the study provides a comprehensive picture of treatment selection, clinical outcomes, treatment goals and current limitations of treatments as perceived by physicians and their patients.

Though many efforts were undertaken to overcome these, this study has limitations inherent to the retrospective nature of the chart review study, the descriptive nature of the statistical analyses and the subjective nature of the physician survey. It is further possible, that the results were confounded by potential factors that were not identified. A key limitation for analyses related to the early non-responders was the small sample size \((n = 26)\) which may have led to us not being able to identify specific patient characteristics for this patient subgroup. Also, it must be kept in mind that inclusion criteria required patients to have completed at least two lines of therapy and that a quota for survival status was used to ensure that 80% of patients were still alive at the date of data abstraction. While this ensured that there are sufficient data on treatment patterns in first- and second line, it may bias results towards “healthier” or longer living patients in this population. For this reason, the analysis of OS must be considered with caution.

Despite these limitations the sample of physicians was representative of physicians treating mBC in the US and the current study provides important insights about real world outcomes for ER+ HER2 mBC patients and their current unmet medical need.

**Conclusion**

This study provides new evidence on treatment patterns and real-world clinical outcomes for post-menopausal ER+ HER2- metastatic breast cancer patients in the US. The retrospective chart review revealed that a majority of 82% of patients received endocrine therapy as first-line treatment and showed that current therapies in ER+ HER2-
mBC still result in a short time to progression in first line. In the accompanying survey, physician considered limited efficacy and tolerability as the main deficiencies of current treatments, and consider improvements of quality of life as an important treatment goal. The overall finding from this study highlight a quantitative unmet need for more effective treatments which delay disease progression and improve survival outcomes while maintaining quality of life.

Abbreviations
ASCO: American Society of Clinical Oncology; BC: Breast Cancer; ECOG: Eastern Cooperative Oncology Group; ER+: Estrogen receptor-positive; ET: Endocrine Therapy; HER2+: Human Epidermal Growth Factor Receptor 2 negative; IRB: Institutional Review Board; mBC: Metastatic Breast Cancer; NCCN: National Comprehensive Cancer Network; OS: Overall Survival; PFS: Progression-free Survival; TTP: Time to progression; US: United States

Acknowledgements
The following contributor is acknowledged: Shrividya Iyer, an employee of Pfizer, for scientific advice.

Funding
Pfizer contracted and funded Mapi to undertake this study. This study was designed and sponsored by Pfizer, with assistance from MAPI; the physician survey was also developed by employees of Pfizer, along with employees of MAPI. Data analyses were done by Mapi, interpretation of the data was done by Pfizer and MAPI employees together. Each of the Pfizer and MAPI authors listed on this publication contributed, as disclosed on the below section. Editorial/medical writing support was provided by Carole Mamane at Mapi and was funded by Pfizer.

Availability of data and materials
The data that support the findings of this study are available from the sponsor but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the sponsor.

Authors’ contributions
MM (MAPI) and GZ (Pfizer) designed the study and along with JP (Pfizer) and RH (Pfizer) also developed the physician survey. MH (Mapi) conducted the statistical analysis. All of the authors (GZ, MH, JP, RH, MM) have interpreted the data, read and corrected draft versions of the manuscript and approved the final manuscript.

Competing interests
Matthias Hunger is employed by Mapi. Monique Martin was employed by Mapi at the time the study was conducted and is now an employee of InVentiv Health. Giovanni Zanotti and Julia Perkins are employed by Pfizer. Ruslan Horblyuk was employed at Pfizer during the conduct of the study and initiation of the manuscript.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Institutional Review Board (IRB) approval was obtained for both the physician survey and the patient medical record data extraction components of this study (Schulman IRB number 201500093). The need for informed consent from patients was waived. Physicians provided consent to participate in the study as requested by the IRB. Research was performed in accordance with the Declaration of Helsinki.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Mapi, Konrad-2-use-Platz 11, 81829 Munich, Germany. 2Pfizer Inc, 235E 42nd, New York, NY 10017, USA. 3Mapi, Beaufort House, Cricket Field Road, Uxbridge UB8 1OG, UK.

Received: 5 August 2016 Accepted: 22 May 2017
Published online: 02 June 2017

References
1. Jemal A, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
2. American Cancer Society, Cancer Facts and Figures 2015. 2015.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5–29.
4. O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl 3):20–9.
5. Metastatic Breast Cancer Network. Incidence and Incidence Rates. 2016 Oct [Cited 2016 14 Nov]; Available from: http://www.mbcn.org/incidence-and-incidence-rates/.
6. Metastatic Breast Cancer Network: 13 Facts About Metastatic Breast Cancer. 2016 [cited 2016 14 Nov]; Available from: http://www.mbcn.org/13-facts-about-metastatic-breast-cancer/.
7. Metastatic Breast Cancer Network. Survival rates. 2016 [cited 2016 14 Nov]; Available from: http://www.mbcn.org/3957-2/.
8. American Society of Clinical Oncology, The 2008 ASCO Breast Cancer Symposium. 2008: Washington, DC.
9. Yamamoto-Ibusuki M, Amedosi M, Andre F. Targeted therapies for ER+/HER2- metastatic breast cancer. BMC Med. 2015;13:137.
10. Buzdar AU. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol. 2004;22(15):3199–200. author reply 3200-1.
11. National Comprehensive Cancer Network, NCCN Practice Guidelines in Oncology. 2016. p. 35.
12. Boswell KA, et al. Disease burden and treatment outcomes in second-line therapy of patients with estrogen receptor-positive (ER+) advanced breast cancer: a review of the literature. Breast. 2012;21(6):701–6.
13. Swallow E, et al. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2−) breast cancer patients in the United States: 2002-2012. Curr med res Opin. 2014;30(8):1537–45.
14. Li N, et al. Everolimus-based therapy versus chemotherapy among patients with HR+/HER2- metastatic breast cancer: comparative effectiveness from a chart review study. Int J Breast Cancer. 2015;2015:240750.
15. Macalald, A.R, et al., Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004–2010). Curr Med Res Opin. 2015. 31(2): p. 268 Figure 2.
16. Xie J, et al. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US. Exp Hematol Oncol. 2015;4:31.
17. Gao S, et al. Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe. Curr Med Res Opin. 2012;28(7):1111–8.
18. Bonnetterre J, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol. 2000;18(22):3748–57.
19. Nabholz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women results of a north American multicenter randomized trial. Arimidex Study Group J Clin Oncol. 2000;18(22):3758–67.
20. Robertson JF, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the FIRST-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study. Breast Cancer res Treat. 2012;136(2):S03–11.
21. Geisler J, et al. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer res. 2008;14(19):6330–5.
22. Dixon JM, et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol. 2008;26(10):1671–6.
23. Sendur MA, et al. Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer. J BUON. 2013;18(4):838–44.

24. Xie J, et al. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2-metastatic breast cancer: a retrospective chart review in community oncology practices in the US. Curr med res Opin. 2015;31(6):1095–103.